Apyx Medical Corp
APYX Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$2.46
KIRA · Stoqly’s AI analyst, in plain words
- Apyx Medical Corp had $52.8M of revenue in fiscal 2025, up 9.9% on the year before. Over five years, revenue changed +13.8% a year on average.
- Its operating margin was −12.2%, up 27.0 pts: of every 100 in sales, about −12 is left after running the business.
- Apyx Medical Corp lost $11.2M in fiscal 2025.
- Free cash flow was −$9.1M in fiscal 2025, −17.2% of revenue.
- Apyx Medical Corp owes $5.8M more than it holds in cash.
Market cap
—
P/E
—
Revenue
$52.8M
Net income
−$11.2M
Free cash flow
−$9.1M
Operating margin
−12.2%
Apyx Medical Corp in 30 seconds · fiscal 2025
Are sales growing?
+9.9%
Yes. Sales grew 9.9% last year.
Does it make a profit?
−21.2%
No. It lost money last year.
Does profit turn into cash?
−17.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
What Apyx Medical Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Apyx Medical Corp
- CIK
- 0000719135
Apyx Medical Corp · APYX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $48.5M | $44.5M | $52.3M | $48.1M | $52.8M |
| Revenue growth | 75.1% | −8.3% | 17.6% | −8.1% | 9.9% |
| Gross margin | 69.3% | 65.4% | 64.5% | 61.0% | 62.5% |
| Operating margin | −29.8% | −52.9% | −33.0% | −39.2% | −12.2% |
| Net income | −$15.2M | −$23.2M | −$18.7M | −$23.5M | −$11.2M |
| Net margin | −31.3% | −52.1% | −35.7% | −48.8% | −21.2% |
| Diluted EPS | −$0.44 | −$0.67 | −$0.54 | — | — |
| Cash | |||||
| Cash from operations | −$10.4M | −$20.3M | −$5.2M | −$18.0M | −$8.0M |
| Capital expenditure | $0.7M | $1.0M | $0.5M | $0.7M | $1.1M |
| Free cash flow | −$11.2M | −$21.3M | −$5.8M | −$18.8M | −$9.1M |
| FCF margin | −23.0% | −47.8% | −11.0% | −39.0% | −17.2% |
| Share count change | 0.4% | 0.5% | 0.3% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $30.9M | $10.2M | $43.7M | $31.7M | $31.7M |
| Debt incl. finance leases | — | $0.1M | $33.3M | $37.6M | $37.5M |
| Shareholders' equity | $53.7M | $37.6M | $26.7M | $14.2M | $14.5M |
| Current ratio | 4.6x | 3.6x | 5.5x | 5.3x | 5.0x |
| Interest coverage | −1,444.8x | −1,570.8x | −7.0x | −3.2x | −1.2x |
| Returns and quality | |||||
| Return on capital | — | −68.0% | −84.0% | −74.6% | −25.1% |
| Return on equity | −25.8% | −50.8% | −58.2% | −114.7% | −78.0% |
| Return on tangible equity | −28.3% | −61.7% | −70.1% | −165.1% | −77.1% |
| Piotroski F-score | 3 | 2 | 3 | 2 | 5 |
| Altman Z'' | 6.4 | 1.5 | 1.6 | −0.9 | −0.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Apyx Medical Corp · APYX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.46 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0000719135). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.